With respect to a potential role for CD44 in neuronal tumors, we investigated the regulation of variant CD44 exon containing isoforms (CD44V) in the human neuroblastoma cell line SK-N-SH in response to treatment with dierentiation-inducing and mitogenic factors. While the standard form of CD44 was expressed at high levels in both treated and untreated cells, variant isoforms were strongly upregulated in response to treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), insulinlike growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as shown by RT ± PCR and immunouorescence. One of the CD44 isoforms contains sequences encoded by variant exon v6 (CD44V6), which was originally described as a metastasis-associated antigen. Using speci®c inhibitors, we explored the signal transduction pathways involved in the expression of variant CD44. GF-109203X, a speci®c inhibitor of protein kinase C eectively blocked TPA-and IGF-1-upregulated expression of CD44v6. Wortmannin, a speci®c inhibitor of phosphoinositide 3-kinase (PI 3-kinase) partly reduced IGF-1 and PDGF induced CD44v6 expression. The induction of CD44V by TPA, IGF-1 or PDGF was correlated with an increased cellular binding to hyaluronic acid, a major counterreceptor for CD44. The increased binding caused by TPA or IGF-1 could speci®cally be blocked by the above inhibitors. Thus, PKC and PI 3-kinase are likely to transduce growth factor induced signals that upregulate speci®c CD44 splice variants.
Introduction
The human CD44 family of transmembrane receptor molecules is derived from a single gene located on chromosome 11. The gene consists of at least 19 exons, ten of which encode the standard form of CD44 (CD44S) with an apparent molecular weight of 85 ± 90 kD. Nine (v2-v10) of ten variant exons (v1-v10) can be subject to alternative splicing of the pre-mRNA. They contribute to higher molecular weight forms termed CD44 variants (CD44V) in combination with the standard exons ( Figure 1 ). All CD44 isoforms are variably glycosylated. (CD44 capital -S or -V designates protein, small -s or -v, nucleic acid) (for review see: GuÈ nthert, 1993) .
There is evidence for a role of CD44 as a receptor which mediates binding of lymphocytes and epithelial cells to extracellular matrix ligands or counterreceptors such as hyaluronic acid, ®bronectin and collagen (Aruo et al., 1990; Jalkanen and Jalkanen, 1992; Stamenkovic et al., 1991) . The adhesiveness of CD44 to its major ligand hyaluronate is in¯uenced by exon composition, glycosylation status and local patching of the molecules within the plasma membrane (Dougherty et al., 1994; Katoh et al., 1995; Sleeman et al., 1996) . Recently, a new function has been described for isoforms containing exon v3 sequences as growth factor presenting molecules. Possibly, this property is relevant in embryogenesis (Bennett et al., 1995; Sherman et al., 1994) . In contrast to standard CD44, which is widely expressed, CD44V isoforms have a much more restricted distribution (for review see: Sherman et al., 1996) . Metastasis-speci®c variants of CD44 containing the epitope encoded by exon v6 were ®rst described in a rat adenocarcinoma model (GuÈ nthert et al., 1991; Reber et al., 1990) and subsequently seen in other cancers . Especially V6-containing isoforms have been linked to metastatic spreading of a number of animal and human malignancies e.g. lymphomas, renal cell tumors and colon carcinomas (Stauder et al., 1995a; Tanabe and Saya, 1994) . While many tumors show a positive correlation between tumor progression and expression of CD44v Terpe et al., 1994; Wielenga et al., 1993) , neuroblastomas, highly malignant tumors derived from the neuronal crest, exhibit an inverse correlation between CD44S expression and tumor progression (Christiansen et al., 1995b; Combaret et al., 1995; Shtivelman and Bishop, 1991) .
Established neuroblastoma cell lines have been widely used as model systems for the analysis of parameters of growth control and cellular differentiation of neuronal progenitors as well as for tumor studies (PaÊ hlman et al., 1992) .
A functional role of CD44 within tumor progression and -dissemination is anticipated, but still controversial for human neuroblastoma. We used the neuroblastoma derived human cell line SK-N-SH (Biedler et al., 1973) , an adrenergic line of polyclonal origin with activated N-ras (Hall et al., 1983; Taparowsky et al., 1983) and high c-myc expression (Sadee et al., 1987) . We used agents which were described as inducers of cell growth and dierentiation for these cells to analyse a possible modulation of CD44S-and CD44V-isoform expression. Finding that TPA, IGF-1 and PDGF were eective in modulating CD44V expression, we then employed speci®c inhibitors to further investigate the activation of signal transduction pathways downstream of these agents, that might regulate dierential expression of CD44 variants. Our ®ndings suggest a prominent role for PKC and PI 3-kinase in the dierential expression of CD44 variants in SK-N-SH cells.
Results
Dierential splicing of CD44v mRNA transcripts is upregulated by TPA, IGF-1 and PDGF To analyse CD44 splicing patterns in SK-N-SH cells in response to stimulation with dierentiation-inducing or mitogenic factors, we performed RT ± PCR by using primers speci®c for CD44s and CD44v. The combinations of primers to amplify speci®c exons of CD44 are depicted in Figure 1 . CD44s mRNA was detected as a strong 320 bp PCR band in all samples of SK-N-SH, regardless of treatment ( Figure 2a ). The SK-N-SH derived subclone SH-SY5Y (Biedler et al., 1978) , which was described to be negative for CD44 did not show any transcript for CD44s or CD44v (Figure 2a ± g) (Gross et al., 1994) . In unstimulated CD44 SK-N-SH cells mRNA with sequences encoded by standard exons plus exons v3, v6, v8 and v9 were expressed. Transcripts including exon v3 were considerably expressed with all conditions except treatment with NGF ( Figure 2b ). For exon v5, a PCR product of 270 bp was ampli®ed only in samples treated with TPA, IGF-1 and PDGF (Figure 2c ). CD44v6 transcripts of 280 bp (v6-C(constant)) were detected in all samples of SK-N-SH. However, band intensities were strongest for cells treated with TPA, IGF-1 and PDGF (Figure 2d ). Transcripts containing the alternate exon v7 of 290 bp (v7-C) and 680 bp (v7-v8-v9-v10-C) were again only upregulated in those samples that were treated with TPA, IGF-1 or PDGF ( Figure  2e ). Accordingly, a similar pattern was seen for alternate exon v8 with a distinct band of about 540 bp (v8-v9-v10-C) (Figure 2f ). Transcripts with exon v9 of about 230 bp (v9-C) and 430 bp (v9-v10-C) were detected in all samples except those treated with conditioned medium of transformed ®broblasts (CM) and nerve growth factor (NGF), where levels were very low (Figure 2g ). Cells treated with TPA, IGF-1 and PDGF expressed v9-containing mRNA at a comparatively higher rate. Thus, depending on the type of inducing agent, signi®cant dierences in the splicing pattern of CD44 variants were detected. The most eective upregulation of CD44v mRNA abundance was observed upon treatment with TPA, IGF-1 or PDGF. Stimulation of cells with transforming growth factor b (TGFb) did not change the abundance of variant CD44 mRNAs when compared to control levels. CM had a suppressive eect on the presence of CD44v6 and v9. Compared to control levels, cells treated with bombesin had slightly lower levels of CD44v3 transcripts. Stimulation with NGF lead to reduced levels of CD44v3, v6 and v9 mRNAs, indicating the presence of functional NGF receptors on SK-N-SH cells. To ensure that closely matched amounts of cDNA were used in the reactions, a portion of the housekeeping gene GAPDH was ampli®ed parallel with the probes. Equal amounts of GAPDH were detected in all samples of SK-N-SH ( Figure 2h ).
As mitogens can stimulate the CD44 promoter, we wanted to ensure that the upregulation of the dierentially spliced CD44v mRNAs was not simply a consequence of the overall increase in total CD44 mRNA, possibly due to an increased activation of the promoter, with the variants only representing a constant fraction of CD44 message. To this end, Northern blot analysis was performed using a probe containing a CD44s-derived sequence present in all splice variants (Figure 3 ). RNA was blotted from SK-N-SH cells that were either unstimulated, or stimulated with TPA, IGF-1 or PDGF for one day. Within that time frame, all three agents failed to alter the amount of total CD44 mRNA signi®cantly compared to that seen in unstimulated cells. Besides being possible inducers of transcriptional activity, all three agents are therefore likely to be speci®c regulators of CD44V expression in SK-N-SH cells.
Epitopes encoded by CD44s and CD44v6 are expressed on the surface of SK-N-SH neuroblastoma cells and are upregulated by TPA, IGF-1 and PDGF
As a relative increase in dierentially spliced CD44 mRNAs was detected with treatment by TPA, PDGF or IGF-1, we investigated whether these agents would also lead to upregulation of variant CD44 (CD44V) protein expression. SK-N-SH cells were treated with TPA, PDGF or IGF-1 and CD44V protein expression was determined by Western blot analysis and¯ow cytometry. Cell lysates were analysed by Western blotting using a CD44 antibody recognizing all isoforms. A predominant CD44 protein of about 85 kD was detected ( Figure 4 ). This form represents the standard CD44 molecule. CD44S was constitutively expressed on all cells independent of a given treatment. The intensity of the band increased about twofold, when TPA, PDGF or IGF-1 were given for 2 days. With a prolonged incubation time compared to that given in the experimental conditions above, these three agents are thus likely to aect overall CD44 expression.
With treatment of SK-N-SH cells by PDGF, the appearance of higher molecular forms of CD44 of about 97 to 200 kD became visible. Measuring the optical density, quantitative analysis of these upper bands revealed that the amount of higher molecular weight forms was below 4% of total CD44. Surface expression analysed by¯ow cytometry showed that close to 100% of both untreated and treated cells constitutively expressed the standard CD44 molecule (data not shown).
We further concentrated on monitoring of CD44V6 as a potentially critical variant isoform. This was especially done with respect to the potential role of this epitope for metastasis formation (for review see: Tanabe and Saya, 1994) . As is depicted in Figure 5 , untreated cells (control) expressed the epitope encoded by exon v6 at low levels of about 7% positive cells. In contrast to CD44S, a strong upregulation of CD44V6 was observed upon treatment with TPA, IGF-1 and PDGF. Compared to control levels, the addition of TPA lead to an about threefold increase in CD44V6 expression. IGF-1 treatment increased CD44V6 expression by about fourfold. The stimulation with PDGF markedly upregulated CD44V6 expression by about sevenfold.
Induced upregulation of CD44V6 isoforms is modulated by speci®c signal transduction inhibitors
To further investigate signal transduction pathways that might regulate dierential expression of CD44 variants, we employed speci®c inhibitors that antagonize TPA, IGF-1 and PDGF by blocking components of the respective signaling routes (Figure 5a ). GF-109203X, a speci®c inhibitor of PKC blocked CD44V6 expression by TPA and IGF-1 completely (Figure 5b ). Cells were stimulated with TPA (100 ng/ml), IGF-1 (50 ng/ml) or PDGF (50 ng/ml) for 2 days. Cell lysates (10 mg protein/lane) were run on a 8% SDS ± PAGE under nonreducing conditions and detected with the Western Light System (Tropix). The mAb BU52 is speci®c for an invariant domain of CD44
CD44 isoform regulation by PI 3-K and PKC M Fichter et al GF-109203X reduced PDGF-induced upregulation of CD44V6 by 25%. Wortmannin a speci®c inhibitor of PI 3-kinase reduced CD44V6 expression induced by IGF-1 and PDGF by 31% and 18%, respectively ( Figure 5c ). The TPA-induced upregulation of CD44V6 was not aected by the inhibitor Wortmannin ( Figure 5c ). The level of CD44S expression was not seen to be eected by either GF-109203X nor Wortmannin after 2 days of incubation (data not shown).
Induced upregulation of CD44V6 isoforms correlates with cell adhesion to hyaluronate (HA)
To examine possible functional implications of CD44V upregulation, we measured cellular binding to HA, a reported high anity ligand of CD44. We investigated whether the changes in expression displayed in Figure 5 resulted in changes in the binding capacities of SK-N-SH cells to HA-coated plates.
51
Cr-labeled cells were thus plated into wells either preincubated with PBS alone or coated with chondroitin-6-sulphate (ChS) or polymeric HA.
TPA stimulation increased the binding to HA by a factor of ®ve (Figure 6c ). This TPA induced binding to HA was completely blocked by the PKC-speci®c inhibitor GF-109203X. The PI 3-kinase-speci®c inhibitor Wortmannin was not included in this panel as it did not result in any signi®cant change in CD44V6 expression with TPA treated cells (Figure 5c) .
Stimulation with IGF-1 led to about 12-fold increase in cellular HA binding compared to unstimulated cells. The addition of Wortmannin resulted in a reduction in IGF-1 induced binding to HA by 65%. GF-109203X reduced that binding to near control levels. Stimulation with IGF-1 resulted in a slight increase in binding to PBS and ChS pretreated plates (three-and twofold respectively), which was completely reduced by both inhibitors.
The highest increase in HA binding was observed after treatment of cells with PDGF (about 18-fold). The PDGF-induced increase in HA binding was reduced by 60% with GF-109203X and by 64% with Wortmannin. Only minute eects were seen with these inhibitors with respect to the binding of PDGF treated cells to PBS and ChS pretreated plates (Figure 6a and  b) .
A combination of Wortmannin and GF-109203X was used to study the combined eect of both inhibitors after PDGF treatment of SK-N-SH cells. This treatment, however, resulted in phenotypical alterations that suggested cytotoxicity and were therefore not included in this panel. Results obtained with lovastatin, a ras inhibitor, were omitted for similar reasons.
Discussion
In the present study, we report regulation of CD44S and CD44V expression in the neuronal tumor cell line SK-N-SH. Finding that PDGF, IGF-1 and TPA upregulate expression of CD44V we have utilized two relatively speci®c inhibitors to show that PI 3-kinase and PKC are likely to be involved in the upregulation of the dierentially spliced variant CD44 isoforms.
So far, little is known about the regulation of CD44 expression in neuronal cells, as well as in tumor cells of neuronal origin. Shtivelman and Bishop (1991) have reported that CD44 is generally downregulated in neuroblastoma cells. Another group has stated that neuroblastoma cell lines, including SK-N-SH, generally lack variant CD44 isoforms (Gross et al., 1994 (Gross et al., , 1995 . Clinical studies have shown an inverse correlation between the expression of CD44S and N-myc ampli®cation (Christiansen et al., 1995a; Combaret et al., 1995; Gross et al., 1994) . High CD44S expression and a lack of N-myc ampli®cation correlate with a good prognosis for patients with neuroblastoma. In neuronal tumor cell lines, CD44 was detected only in those cell lines that have no N-myc ampli®cation (Gross et al., 1994) . Consistent with these data, we detected the standard form of CD44 in the neuroblastoma cell line SK-N-SH, as con®rmed by RT ± PCR,¯ow cytometry and Western blot analysis. We found comparatively high expression of CD44S. In addition, we were able to show that mRNA transcripts encoding distinct variable isoforms are expressed in this cell line. Therefore, we investigated, whether the expression of CD44S and the metastasis-associated isoform CD44V6 can be modulated by dierent stimuli. We concentrated especially on CD44v6-derived mRNA species and CD44 proteins that include the V6 epitope, as these CD44 splice-forms have been strongly associated with tumorigenesis and metastasis (for review see Sherman et al., 1994) . In the context of cells of hematopoetic origin, lymphocyte activation is associated with changes in the expression levels and the appearance of CD44 variant isoforms (Arch et al., 1992; Stauder and GuÈ nthert, 1995b) . Several agents that induce B and T cell activation and proliferation were reported to lead to an upregulation of CD44 variants in these cells. By analogy we used the two growth factors IGF-1 and PDGF, agents that can induce cell proliferation, and the tumor-promoting and in¯ammatory agent TPA. All three were eective in upregulating CD44 mRNA transcripts carrying the alternate exons v3, v5, v6, v7, v8 and v9 without detectably changing total mRNA levels for CD44.
It is well established that growth factor receptor tyrosine kinases can activate distinct signaling pathways. Among these are (i) the Ras induced Raf-MEK-MAPK kinase cascade, (ii) the PLCg mediated pathway resulting in the activation of PKC-isoforms and calmodulin kinase II, and (iii) the pathway induced by PI 3-kinase leading to the generation of phosphoinositide-3-phosphate (PIP 3 ) whose function is still under discussion (for review see Blos, 1995; De Camilli et al., 1996) . All three pathways seem to be interconnected; e.g. Ras can directly interact with the p110 catalytic subunit of the PI 3-kinase (Kodaki et al., 1994; Rodriguez-Viciana et al., 1994) or PKCa can directly phosphorylate the Raf1 kinase (Kolch et al., 1993; Sozeri et al., 1992) . Ras has been shown to induce both, CD44 promoter activity and splice control. Using an inducible v-ras expression-construct, transient Ras overexpression for 24 h resulted in a fourfold increase of overall CD44 mRNA, whereas the induction of CD44v-containing mRNA was about eightfold .
The PKC inhibitor blocked TPA and IGF-1 induced upregulation of CD44V isoforms completely, whereas that induced by PDGF was only partly aected. The PI 3-kinase inhibitor aected only PDGF and IGF-1 induction. Thus, both kinases participate in regulating the dierential expression and possibly splicing of CD44 variants after activation of these growth factor receptors with intrinsic tyrosine kinase activity. Concordant with its role as a PKC activator, TPA induced upregulation of CD44V is independent of PI 3-kinase and is not aected by Wortmannin. The fact that GF-109203X can completely block CD44V6 upregulation induced by IGF-1 but that induced by PDGF only in part suggests a dierential usage of downstream signaling elements through both receptors. It remains unclear why we did not see downregulation of CD44S after incubation of cells with both inhibitors. The expression of CD44S was shown to be responsive to TPA, serum and growth factors and oncogenes like ras, src and her/neu Jamal et al., 1994; Zhu and Bourguignon, 1996) . V-Ras signals upstream and activates PI 3-kinase as well as PKC (Kodaki et al., 1995) . Thus, it seems likely that both inhibitors aect CD44S levels over time.
We have studied CD44 RNA levels and CD44S expression in a lymphoblastic cell line that is immortalized through a mutant Epstein Barr Virus in a conditional fashion (Kempkes et al., 1995) . In this cell-line, CD44 mRNA, as well as CD44S protein levels were both upregulated through a conditionally active Figure 6 Induced increase in cellular binding to HA. SK-N-SH cells were treated with TPA (100 ng/ml), IGF-1 (50 ng/ml) or PDGF (50 ng/ml) for 2 days. Inhibitors GF-109203X (100 ng/ml) and Wortmannin (50 nM) were given 1 h prior to stimulation. Such treated cells were 51 Cr-labeled and transferred to either PBS (a), ChS (b) or HA (c) coated wells. The relative binding was then determined as described in Materials and methods CD44 isoform regulation by PI 3-K and PKC M Fichter et al viral protein EBNA2. Relative CD44 mRNA levels remained stable over 3 days after inactivation of EBNA2, as well as after addition of Wortmannin and GF-109203X for 1 day (Ueng et al., 1996) . Thus, it seems likely that a loss of an inducer activity or repression of transcription by these inhibitors, both mechanisms that eventually aect overall CD44 mRNA levels get apparent much slower than a loss of CD44v mRNA or of isoforms that carry variant epitopes. The above inhibitors did both interfere with the upregulation of CD44V expression as well as HA binding in these lymphoblasts. This ®nding supports the hypothesis, that PI 3-kinase and PKC are cellular signal transducers for CD44V upregulation.
To investigate whether alterations in CD44V-isoform expression were accompanied with functional changes, we performed cellular adhesion assays using the CD44 receptor hyaluronate (HA) as a binding matrix. Increases in HA content have been observed in areas of cell proliferation and migration. The promoting eect of HA on cell migration and homing is due to its ability to form an expanded, highly hydrated bed which facilitates cell to extracellular matrix contacts. Additionally, cytokines and chemokines may be bound by the HA matrix and thus be presented in locally dierent concentrations (reviewed by Tanaka et al., 1993) .
The stimulation of SK-N-SH cells with TPA, IGF-1 and PDGF led to a dramatic increase in cellular binding to HA-coated plates. Both inhibitors could antagonize the binding. Although increases in binding corresponded well with the¯ow cytometry data regarding the up-regulation of the CD44V6 isoform by TPA, IGF-1 and PDGF, the fold increase in binding exceeded the increase of FACS-detected protein expression on the cell surface. Thus, in addition to quantitative changes of the expressed CD44V isoforms, the three agents may also induce qualitative changes of CD44 molecules which aect binding. CD44 binding to HA may not only be in¯uenced by exon composition, but may also be determined by glycosylation status and/or local distributions of the molecule (Dougherty et al., 1994; Katoh et al., 1995) . In addition, there is evidence that exon v6 is expressed in combination with exons v4, v5, and v7 or together with exon v7 alone . RT ± PCR analysis of TPA, IGF-1 or PDGF stimulated SK-N-SH cells suggests upregulation of CD44 isoforms that contain variant epitopes, like V3, V5, V6, V7, V8 and V9. Thus, it is well possible, that other epitopes than V6 are important for induction of increased HA binding of SK-N-SH.
A recent study demonstrates that overexpression of p185 neu upregulates CD44 in NIH3T3 cells and, in consequence, results in a dramatically increased binding of these cells to HA (Zhu and Bourguignon, 1996) . The authors did not investigate a possible induction of speci®c CD44 variant isoforms. Their results, however, imply that in addition to the transient action of normal, cellular protooncogene products such as the PDGF-and IGF-1 receptors, fully oncogenic and constitutively active tyrosine kinase receptors like p185 neu can result in the permanent upregulation of CD44.
In conclusion, this study demonstrates that mitogeninduced pathways regulate the expression of variant CD44 isoforms. The level of CD44V isoform expression, especially CD44V6, can be upregulated by TPA, IGF-1 or PDGF. The induced increase of CD44V6 correlates well with an increase in the binding capacity of such cells to HA. Expression of CD44V and cellular binding to HA are aected by Wortmannin and GF-109203X. We therefore suggest that dierential splicing of CD44 variants can be regulated by distinct signal transduction pathways involving PKC and PI 3-kinase. It would be of interest to study, whether other signal molecules contribute to this regulation or can act independently on it. Finally, the use of such inhibitors as potential therapeutic agents to interfere with metastasis formation in vivo should be investigated.
Materials and methods

Cell culture
Cells were maintained in RPMI 1640 medium with glutamine supplemented with 10% fetal calf serum (FCS), 1 mM pyruvate, and 100 mg/ml penicillin/streptomycin (all from Gibco). For stimulation assays, cells were starved in serum free SHTE medium (PaÊ hlman et al., 1991) . For PCR and Northern blot analysis, cells were starved for 1 day, then stimulated with 10 ng/ml TPA (Gibco), 20 ng/ml IGF-1 (Boehringer-Mannheim), 10 ng/ml PDGF (PeproTech), CM, 30 nM bombesin (Sigma), 50 ng/ml NGF (Gibco) or 10 ng/ml TGFb (PBH) for 1 day. For Western blotting,¯ow cytometry and HA-binding assays, cells were starved for 1 day, then stimulated with TPA (100 ng/ml), IGF-1 (50 ng/ml) or PDGF (50 ng/ml) for 2 days. For HAbinding assays and¯ow cytometry, cells were preincubated with the inhibitors 100 ng/ml GF-109203X (bisindolylmaleimide I, indentical with GoÈ 6850, GoÈ decke) (Toullec et al., 1991) or 50 nM Wortmannin (BIOMOL) for 1 h prior to stimulation.
RNA isolation
Cells were washed with Phosphate Buered Saline (without Ca 2+ and Mg 2+ ) (PBS) and lysed directly on the culture dish with RNAzol B reagent (Tel-Test) (Chomczynski and Sacchi, 1987) . Cellular protein and DNA was extracted with 1/10 volume chloroform and centrifugation at 10 0006g. RNA was precipitated with 1 volume 2-propanol and centrifuged at 10 0006g. RNA pellets were washed once in 70% ethanol, air-dried and resuspended in an appropriate volume of H 2 O at 658C.
cDNA-synthesis 0.5 mg of total RNA were subjected to reverse transcription in a 100 ml reaction using 5 mg random hexamers as primers (Pharmacia) and 12.5 pM of each dNTP. The 106 reaction buer contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3 mM MgCl 2 and 0.01% glycerol. Prior to addition of 5 U AMV reverse transcriptase (Promega) and 10 U Rnasin (Appligene), the reaction mix was heated to 688C for 10 min. cDNA synthesis was carried out for 2 h at 458C.
PCR
PCR reactions were performed under mineral oil in a total volume of 50 ml containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3 mM MgCl 2 , 0.01% glycerol, 10 pM of each primer, 1 unit of Taq polymerase (Promega), 12.5 pM of each dNTP (Pharmacia) and 25 ml of cDNA (the equivalent of 125 ng RNA). The cDNA was ampli®ed in Oligonucleotides for PCR reactions (except for GAPDH) were the same as used by (van Weering et al., 1993) : C13: 5'-AAGACATCTACCCCAGCAAC-3'; C2A: 5'-CCAAGAT-GATCAGCCATTCTGG-3'; pv3: 5'-ACGTCTTCAAATAC-CATCTC-3'; pv4: 5'-TCAACCACACCACGGGCTTT-3'; pv5: 5'-GTAGACAGAAATGGCACCAC-3'; pv6: 5'-CAGG-CAACTCCTAGTAGTAC-3'; pv7: 5'-CAGCCTCAGCTCA-TACCAGC-3'; pv8: 5'-TCCAGTCATAGTACAACGCT-3'; pv9: 5'-CAGAGCTTCTCTACATCACA-3'; GAPDH1: 5'-CGGGAAGCTTGTGATCAATGG-3'; GAPDH2: 5'-GGC-AGTGATGGCATGGACTG-3'. A portion of the GAPDH gene (glycerine aldehyd-3-phosphat-dehydrogenase) (Allen et al., 1987) was ampli®ed along with the probes as an internal control for cDNA quality and quantity. PCR products were analysed on 1.4% agarose gels and photographed with a CCD camera (Cybertech).
Northern blotting
RNAs (20 mg/sample) were separated in 1% agarose ± 6% formaldehyde gels and blotted onto Hybond-N nylon membranes (Amersham) using 206SSC. The RNA blots were hybridized to a 320 bp, random prime 32 P-labeled CD44S probe, as described in Hofmannn et al. (1993) . The relative abundance of RNA per lane was checked by comparison of the ethidium bromide staining of the ribosomal RNA bands and by hybridization of RNAs with a probe to GAPDH. Blots were autoradiographed using Kodak X-OMAT AR5 ®lms, exposed at 7708C.
Western blotting
Cells were harvested and lysed in preheated, non-reducing, modi®ed Laemmli buer (20 mM Tris-Cl, pH 7; 2 mM EGTA, 2 mM EDTA, 1% SDS, proteinase inhibitors Leupeptin (5 mg/ml), Aprotinin (2 mg/ml) and Pefabloc SC (1 mM) and sonicated. Cell extracts were separated by 8% SDS ± PAGE. Protein blotting analysis was performed using the monoclonal antibody BU52 (Binding Site) directed against a constant extracellular CD44 epitope. CD44 proteins were visualized by autoradiography using the Western Light System (Tropix).
Flow cytometry
Fluorescence of cells stained with monoclonal antibodies against CD44S and CD44V6 epitopes (both Bender Med Systems) was measured with the FACScan¯ow cytometer (Becton Dickinson). Data were analysed with the LYSIS II program (Becton Dickinson). Adherent SK-N-SH cells were removed from the culture plates with cold PBS plus 1 mM EDTA. The cells were incubated with a primary anti-CD44 antibody, diluted 1 : 20 in PBS+10% FCS, for 1 h at 48C and then stained with a¯uorescein-labeled secondary antibody (mouse IgG) (DAKO), diluted 1 : 50, for 45 min. The secondary antibody alone was taken as a negative control, de®ning background¯uorescence. Cells were de®ned as positive for a given CD44 isoform when above background¯uorescence. Prior to measurement, the cells were stained with propidium iodide (0.2 mg/ml) in order to identify viable cell populations. Only viable cells were gated and further analysed.
Cell adhesion to hyaluronate (HA)
To study the adhesion of SK-N-SH cells, 24-well plates were coated with 5 mg/ml hyaluronate (Sigma), 5 mg/ml chondroitin-6-sulphate (Sigma) in PBS, or PBS alone. Nonspeci®c binding was blocked by preincubating the coated wells with 10 mg/ml fatty acid free BSA (fraction V, Sigma) at 48C for a minimum of 3 h. 5610 5 cells were stimulated with the aforementioned agents for 48 h, detached with PBS+1 mM EDTA and labeled with 1.5 mCi/ml Na 2 [
51 Cr]O 4 (Amersham) for 2 h at 378C in a cell culture incubator. After centrifugation (300 g, 5 min), the cells were washed twice with RPMI and resuspended. The incorporated radioactivity in these cell suspensions was set as the reference point, de®ned as 100%. Labeled cells were seeded at 1610 5 cells/well in triplicates into the precoated plates and incubated at 48C for 3 h. Subsequently, non-adherent cells were removed from the plates with cold PBS. The adherent cells were lysed with 1% Triton X-100 at room temperature. Cell lysates and the 51 Cr-labeled cell suspensions as standards were transferred to lumaplates (Canberra Packard) as hexaplicates and counted in a TopCount scintillation counter (Canberra Packard).
